Price
CHART BY
Frequently asked questions
What is Illumina's market capitalization?
What is the Earnings Per Share (EPS) for Illumina?
What are the analyst ratings and target price for Illumina's stock?
What is Illumina's revenue over the trailing twelve months?
What is the EBITDA for Illumina?
What is the free cash flow of Illumina?
How many employees does Illumina have, and what sector and industry does it belong to?
What is the free float of Illumina's shares?
Financials
- Market Cap
- $21.57B
- EPS (TTM)
- -$9.996
- Free Float
- 157.38M
- Revenue (TTM)
- $4.39B
- EBITDA (TTM)
- $1.36B
- Free Cashflow (TTM)
- $546.00M
Pricing
- 1D span
- $132.16$138.17
- 52W span
- $97.39$156.66
Analyst Ratings
The price target is $163.91 and the stock is covered by 27 analysts.
Buy
13
Hold
13
Sell
1
Information
Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions. The firm's products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing and microarray services, proactive instrument monitoring, and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.
- Employees
- 12,010
- Industries
- Biotechnology
- Sector
- Health Care
Identifier
- ISIN
- US4523271090
- Primary Ticker
- ILMN